According to a statement on the official website of British American Tobacco (BAT), the company has established an innovation center at its global research and development (R&D) headquarters in Southampton. This center will play a key role in the company's ongoing transformation and in pursuing its vision of creating a "better future".
A facility costing £30 million has enhanced and deepened the research and development capabilities of British American Tobacco, providing nine specially designed technology spaces to help develop the company's low-risk product portfolio. The Innovation Centre is dedicated to researching modern oral nicotine pouches, vape liquids and flavors, heated products, as well as new products beyond nicotine.
This investment will also support work in packaging, engineering, innovation development, and system integration.
The British American Tobacco Company's factory in Southampton has been the location of its research and development operations since 1956. It is one of the largest employers in the region, currently employing over 1,000 staff members from various parts of the UK. Its local supply chain includes over 25 suppliers, spread across more than 30 countries and regions.
British American Tobacco has more than 1,600 research and development experts in countries such as the UK, US, Brazil, Indonesia, Malaysia, and China. In 2021, the company opened an innovation center in Trieste, Italy, and in 2022, in Shenzhen, China. British American Tobacco invests 3 billion pounds annually in research and development to develop new category products and establish evidence.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
